Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

Notified -...

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

Notified -...

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Notified -...

menu
menu